Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Reanzen is a South Korean biotechnology company specializing in the development and manufacture of medical aesthetic products, with a primary focus on botulinum toxin and hyaluronic acid fillers. The company's flagship product, ReanTox, is a high-purity Botulinum Toxin Type A used for various cosmetic and therapeutic indications, including the reduction of facial wrinkles and treatment of muscle-related conditions. Reanzen operates a dedicated manufacturing facility in South Korea that complies with global GMP standards to ensure the safety and efficacy of its biological products. The company is actively expanding its global footprint by securing regulatory approvals in international markets and diversifying its aesthetic portfolio with products like the ReanFill line.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Reanzen.